We have defined the molecular mechanisms whereby interactions of multiple myeloma (MM) cells with BM stromal cells (BMSCs) mediate growth, survival, and drug resistance in the BM milieu using in vitro and in vivo models. We have then validated novel therapeutics targeting the MM cell and its BM microenvironment (bortezomib, lenalidomide and combinations thereof), and rapidly translated these agents from bench to bedside and FDA approval. The current proposal will further define the molecular, functional, and therapeutic relevance of interactions of MM cells with accessory cells in the BM milieu. Our central hypothesis is that the interaction between MM cells and their surrounding accessory cells in the BM microenvironment is a bidirectional one, whereby MM cells prime the accessory cells to function as more potent inducers of MM cell proliferation, survival, and drug resistance. To address this hypothesis, we will characterize the molecular and functional impact of MM cells on BMSCs as accessory cells in the BM microenvironment (Specific Aim 1);define the role of MM-induced myeloid-derived suppressor cells (MDSCs) as candidate accessory cells directly supporting proliferation and drug resistance of MM cells in the BM (Specific Aim 2);and define the impact of MM cells on accessory cells in vivo and its therapeutic implications. Our studies will provide the framework for a new treatment paradigm, whereby the mechanism(s) of BM accessory cell priming by MM cells constitute bona fide target(s) for therapeutic interventions to overcome drug resistance and improve patient outcome.
Multiple myeloma (MM) affects yearly 20,000 new individuals in the United States and remains incurable. Novel treatment strategies are therefore urgently needed. We have defined the molecular mechanisms whereby interactions of MM cells with bone marrow stromal cells (BMSCs) mediate growth, survival and drug resistance and validated and rapidly translated novel therapeutics (bortezomib and lenalidomide) and combinations regimens from bench to bedside and FDA approval. The current proposal will define the molecular mechanisms and therapeutic implications of how MM cells induce accessory cells of the bone marrow (BM) to more potently support MM cell proliferation and drug resistance. These studies will provide the basis for new treatment paradigms of targeting these interactions to overcome drug resistance and improve patient outcome in MM.
|Hu, Y; Song, W; Cirstea, D et al. (2015) CSNK1?1 mediates malignant plasma cell survival. Leukemia 29:474-82|
|Suzuki, R; Hideshima, T; Mimura, N et al. (2015) Anti-tumor activities of selective HSP90?/? inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia 29:510-4|
|Hideshima, T; Mazitschek, R; Santo, L et al. (2014) Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 28:457-60|
|Anderson, K K; Flora, N; Archie, S et al. (2014) A meta-analysis of ethnic differences in pathways to care at the first episode of psychosis. Acta Psychiatr Scand 130:257-68|
|Tian, Ze; D'Arcy, Padraig; Wang, Xin et al. (2014) A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123:706-16|
|Cottini, Francesca; Hideshima, Teru; Xu, Chunxiao et al. (2014) Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med 20:599-606|
|Hideshima, Hiromasa; Yoshida, Yasuhiro; Ikeda, Hiroshi et al. (2014) IKK? inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Int J Oncol 44:1171-6|
|Tai, Y-T; Landesman, Y; Acharya, C et al. (2014) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28:155-65|
|Minami, J; Suzuki, R; Mazitschek, R et al. (2014) Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 28:680-9|
|Ray, A; Tian, Z; Das, D S et al. (2014) A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia 28:1716-24|
Showing the most recent 10 out of 175 publications